Broderick Brian C Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Broderick Brian C lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,200 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Broderick Brian C’s holdings in Pfizer were worth $903,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Balboa Wealth Partners lifted its position in Pfizer by 56.1% during the 3rd quarter. Balboa Wealth Partners now owns 30,198 shares of the biopharmaceutical company’s stock worth $874,000 after buying an additional 10,852 shares in the last quarter. Oak Harbor Wealth Partners LLC raised its holdings in shares of Pfizer by 3.3% in the third quarter. Oak Harbor Wealth Partners LLC now owns 73,828 shares of the biopharmaceutical company’s stock valued at $2,137,000 after purchasing an additional 2,375 shares during the last quarter. Omnia Family Wealth LLC raised its position in shares of Pfizer by 8.0% in the third quarter. Omnia Family Wealth LLC now owns 8,008 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 591 shares during the period. MeadowBrook Investment Advisors LLC raised its holdings in shares of Pfizer by 8.6% in the 3rd quarter. MeadowBrook Investment Advisors LLC now owns 21,519 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 1,696 shares in the last quarter. Finally, Lifeworks Advisors LLC raised its position in Pfizer by 4.6% in the 3rd quarter. Lifeworks Advisors LLC now owns 195,440 shares of the biopharmaceutical company’s stock worth $5,656,000 after purchasing an additional 8,544 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PFE shares. Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Wolfe Research began coverage on Pfizer in a research note on Friday. They issued an “underperform” rating and a $25.00 price objective on the stock. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Stock Down 2.6 %

Shares of NYSE:PFE opened at $26.02 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a market capitalization of $147.46 billion, a PE ratio of 35.16, a PEG ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50 day moving average price of $28.76 and a two-hundred day moving average price of $28.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.17) earnings per share. Analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.46%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.